Medtronic plc

Medtronic plc is the leading global healthcare technology company, headquartered in Galway, Ireland, serving healthcare systems, physicians, clinicians, and patients in more than 150 countries worldwide. The company operates in the medical device industry, focusing on device-based medical therapies and services across three reportable segments: the Cardiovascular Portfolio, the Neuroscience Portfolio, and the Medical Surgical Portfolio. The company also previously operated a Diabetes Business, but on March 9, 2026, MiniMed Group, Inc. (MiniMed) completed an initial public offering, and during the fourth quarter of fiscal year 2026, the Diabetes Operating Unit was no longer considered a reportable segment.

The filing does not name specific primary competitors or provide market share percentages. The company describes itself as the leading global healthcare technology company and states it is embracing its role as a healthcare technology leader, evolving its business strategy around accelerating innovation-driven growth, delivering superior outcomes and better experiences for patients and providers, and turning data, AI, and automation into action.

Medtronic generates revenue through the development, manufacture, distribution, and sale of device-based medical therapies and services. The company's three reportable segments are the Cardiovascular Portfolio, the Neuroscience Portfolio, and the Medical Surgical Portfolio. The company serves healthcare systems, physicians, clinicians, and patients. The filing does not provide a breakdown of recurring versus transactional income or describe platform or ecosystem dynamics in detail.

The Cardiovascular Portfolio comprises the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular divisions. Cardiac Rhythm & Heart Failure develops products for heart rhythm disorders and heart failure, including implantable cardiac pacemakers such as the Azure MRI SureScan, XT and S models, Adapta, Attesta MRI SureScan, and the Micra transcatheter pacing system; implantable cardioverter defibrillators including the Aurora Extravascular-ICD, Visia AF MRI SureScan, Evera MRI SureScan, Primo MRI SureScan, and the Cobalt and Crome family of BlueSync-enabled ICDs; cardiac resynchronization therapy devices; cardiac ablation products including the PulseSelect and Affera Sphere-360 single shot pulsed field ablation catheters and the Arctic Front Advanced Cardiac Cryoablation System; insertable cardiac monitoring systems including the Reveal LINQ and LINQ II; and the TYRX absorbable antibacterial mesh envelope. Structural Heart & Aortic includes the CoreValve family of aortic valves including the Evolut PRO, Evolut PRO+, Evolut FX, and Evolut FX+ TAVR systems; surgical valve replacement and repair products including the Avalus Ultra surgical valve; endovascular stent grafts including the Endurant II and Endurant IIs Stent Graft System; transcatheter pulmonary valves including Harmony TPV and Melody TPV; left atrial appendage exclusion systems including the Penditure LAA exclusion system; and ECMO systems including the VitalFlow ECMO system. Coronary & Peripheral Vascular includes percutaneous coronary intervention products including the Neuroguard IEP carotid stenting system, Onyx Frontier and Resolute Onyx drug-eluting stents; the Symplicity Spyral renal denervation system; percutaneous angioplasty balloons including the IN.PACT family of drug-coated balloons; and endovenous products including the ClosureFast RFA system and the VenaSeal closure system.

The Neuroscience Portfolio comprises the Cranial and Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. The Medical Surgical Portfolio comprises the Surgical Endoscopy and Acute Care & Monitoring divisions. The filing does not provide specific revenue or margin figures for these individual divisions within the summary sections, but segment-level financial data is provided in the financial statements. The Diabetes Business, prior to its separation, developed and marketed products for diabetes management.

In May 2025, the Company announced its intent to separate the Diabetes Business to create a new independent, publicly traded company, MiniMed Group, Inc. On March 9, 2026, MiniMed completed an initial public offering. During the fourth quarter of fiscal year 2026, the Diabetes Operating Unit was no longer considered a reportable segment. The filing also notes that Medtronic stopped the distribution and sale of the HVAD System in June 2021 and continues a support program for patients with HVAD devices.

For the fiscal year ended April 24, 2026, total net revenue was $34.913 billion ¹, compared to $34.641 billion ² in fiscal year 2025 and $33.270 billion ³ in fiscal year 2024. Net income was $5.148 billion ⁴ for fiscal year 2026, compared to $4.929 billion ⁵ in fiscal year 2025 and $3.758 billion ⁶ in fiscal year 2024. Diluted earnings per share was $3.99 ⁷ in fiscal year 2026, compared to $3.72 ⁸ in fiscal year 2025 and $2.81 ⁹ in fiscal year 2024.

The company states it is embracing its role as a healthcare technology leader and evolving its business strategy in three key areas: accelerate innovation-driven growth, deliver superior outcomes and better experiences for patients and providers, and turn data, AI, and automation into action.

The company aims to accelerate innovation-driven growth, citing the combination of attractive end markets, recent product launches, and a robust pipeline expected to enable continued strong revenue growth. The company states it aims to bring inventive and disruptive technology to large healthcare opportunities and is driven to use its local presence and scale to increase the adoption of its products and services in markets around the globe. The filing does not provide a specific dollar amount for the opportunity size or expected revenue contribution.

The company states it is confident in its ability to maximize new technology, AI, and data and analytics to tailor therapies in real-time, facilitate remote monitoring and care delivery, and create new standards of care. The filing does not provide specific timelines or milestones for these initiatives.

The filing does not provide specific margin or cost outlook figures, margin trajectory, or efficiency targets.

The filing does not provide specific operational outlook details regarding supply chain posture, manufacturing capacity, technology infrastructure investments, or headcount strategy.

The filing does not provide specific figures for R&D spending levels, capital expenditure plans, share repurchase authorization amounts, or dividend policy in the outlook section. However, the financial statements show research and development expense was $2.825 billion ¹⁰ in fiscal year 2026, $2.826 billion ¹¹ in fiscal year 2025, and $2.767 billion ¹² in fiscal year 2024.

The filing does not explicitly flag structural headwinds or execution risks to the growth plan in a dedicated outlook section, though risk factors are discussed in Item 1A.

The filing does not explicitly identify geographic, regulatory, or macro factors as constraints in a dedicated outlook section.

The company faces material risks from pricing pressure and reimbursement challenges, as healthcare policy changes and cost-containment efforts by governments and private payers could reduce the prices paid for its products. The company is subject to extensive government regulation, including by the U.S. FDA and non-U.S. regulatory bodies, and any delay or denial of regulatory approvals for new products or post-approval requirements could materially affect revenue. The company's international operations expose it to risks from geopolitical conflicts, currency exchange rate fluctuations, and changing governmental trade policies and tariffs. The company faces significant litigation and investigation risks, including product liability claims, intellectual property disputes, and government investigations, which could result in substantial costs. The company's restructuring and cost-saving initiatives may not achieve their intended benefits, and the separation of the Diabetes Business into MiniMed Group, Inc. involves execution risks. The company's supply chain and manufacturing operations are subject to potential reduction or interruption, which could adversely affect its ability to meet customer demand.

Management's message emphasizes the company's mission 'to contribute to human welfare by the application of biomedical engineering in the research, design, manufacture, and sale of products to alleviate pain, restore health, and extend life.' The strategic priorities emphasized for the period ahead are: accelerating innovation-driven growth, delivering superior outcomes and better experiences for patients and providers, and turning data, AI, and automation into action.